SCHEMBL6428237

SCHEMBL6428237

CN(C(=O)CC1SC(NC2CCCCC2)=NC1=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.48
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
POLQ O75417 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CASP3 P42574 1/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TP53 P04637 1/20 0.35
MEN1 O00255 1/20 0.35
MITF O75030 1/20 0.35
KMT2A Q03164 1/20 0.35
PAX8 Q06710 1/20 0.35
BTK Q06187 1/20 0.35
GFER P55789 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ELANE P08246 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6426356 1.00 PKM (0.48) PKMMAPTSMN1; SMN2POLQALDH1A1
SCHEMBL6425910 0.99 PKM (0.46) PKMMAPTSMN1; SMN2POLQALDH1A1
SCHEMBL6428317 0.94 PKM (0.40) PKMMAPTPOLQALDH1A1LMNA
SCHEMBL6427997 0.89 PKM (0.40) PKMMAPTSMN1; SMN2ALDH1A1CASP3
SCHEMBL6500646 0.88 MAPT (0.41) MAPTSMN1; SMN2ALDH1A1CASP3NPC1
SCHEMBL6428549 0.86 KMT2A (0.45) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL6428045 0.86 PKM (0.40) PKMMAPTSMN1; SMN2POLQALDH1A1
SCHEMBL6429086 0.85 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1LMNAKDM4ENPC1
SCHEMBL6428801 0.85 NPC1 (0.42) PKMMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL6427221 0.82 MAPT (0.38) MAPTSMN1; SMN2POLQALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 PKM 1152/4885MAPT 3607/4885SMN1; SMN2 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.